Site Group Page (HTP records: those reporting > 100 non-redundant sites)
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Site Group Page (HTP records: those reporting > 100 non-redundant sites)
 

Site Information
SOGA2 (human) S1421-p EDVTPPLsPDDLKYI Links 1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
SOGA2 (mouse) S1407-p EDVTPPLsPDDLKYI Links 7, 29, 32
SOGA2 (rat) S1522-p EDVTPPLsPDDLKYI Links 10

Records

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

5

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

8

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

9

Mulhern D (2012) CST Curation Set: 13543; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(s/t)(phosphorylation)
Curated Info

10

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

11

Mulhern D (2011) CST Curation Set: 12647; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

12

Mulhern D (2011) CST Curation Set: 12863; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

13

Mulhern D (2011) CST Curation Set: 12864; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

14

Mulhern D (2011) CST Curation Set: 12865; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

15

Mulhern D (2011) CST Curation Set: 12640; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

16

Mulhern D (2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

17

Mulhern D (2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

18

Mulhern D (2011) CST Curation Set: 12552; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

19

Mulhern D (2011) CST Curation Set: 12440; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

20

Mulhern D (2011) CST Curation Set: 12442; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

21

Mulhern D (2011) CST Curation Set: 12443; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

22

Moritz A (2011) CST Curation Set: 12381; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

23

Moritz A (2011) CST Curation Set: 12382; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

24

Moritz A (2011) CST Curation Set: 12383; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

25

Moritz A (2011) CST Curation Set: 12384; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

26

Moritz A (2011) CST Curation Set: 12385; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

27

Moritz A (2011) CST Curation Set: 12386; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

28

Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

29

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

30

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

31

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

32

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

33

Zhou J (2010) CST Curation Set: 10710; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

34

Zhou J (2010) CST Curation Set: 10711; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

35

Zhou J (2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

36

Zhou J (2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

37

Guo A (2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

38

Guo A (2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

39

Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

40

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

41

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

42

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

43

Possemato A (2009) CST Curation Set: 7398; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

44

Possemato A (2009) CST Curation Set: 7397; Year: 2009; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation)
Curated Info

45

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

46

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

47

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

48

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info

49

Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92
16964243   Curated Info

50

Nousiainen M, et al. (2006) Phosphoproteome analysis of the human mitotic spindle. Proc Natl Acad Sci U S A 103, 5391-6
16565220   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.